AAN 2026: Head-to-Head Trial Shows Superiority of Qulipta for Migraine Prevention

Why It Matters

The trial provides robust head‑to‑head evidence that an oral gepant can deliver superior tolerability and comparable efficacy to traditional oral preventives and injectable mAbs, potentially reshaping prescribing habits and payer policies in migraine care.

Key Takeaways

• Qulipta cut discontinuations to 12.1% vs 29.6% for topiramate.
• 73.7% of Qulipta patients achieved >50% migraine reduction vs 48.5% with topiramate.
• Head‑to‑head data support AHS recommendation for gepants as first‑line therapy.
• Qulipta shows comparable efficacy to Aimovig, with earlier onset of benefit.
• Results may pressure payers to relax step‑through reimbursement rules in Europe.

Pulse Analysis

The migraine prevention market has undergone a paradigm shift as clinicians move away from legacy oral agents toward targeted therapies. Anti‑CGRP monoclonal antibodies and the newer class of oral gepants have demonstrated higher efficacy and better tolerability, prompting the American Headache Society to endorse them as first‑line options in 2024. This transition reflects growing evidence that disease‑specific mechanisms, rather than broad‑spectrum drugs, deliver meaningful reductions in monthly migraine days while minimizing adverse events.

AbbVie’s TEMPLE Phase IIIb trial adds a decisive data point to this evolving landscape. In a double‑blind, 24‑week head‑to‑head comparison, once‑daily Qulipta (60 mg) reduced treatment‑emergent discontinuations to 12.1% versus 29.6% for topiramate and drove a 73.7% responder rate—patients achieving over a 50% drop in migraine frequency—against 48.5% for the comparator. Secondary analyses confirmed greater absolute reductions in mean monthly migraine days. An indirect cross‑trial comparison with Amgen’s Aimovig suggested similar overall efficacy, but Qulipta delivered a faster onset, highlighting the clinical relevance of oral convenience and rapid symptom control.

These outcomes have immediate commercial implications. Payers in Europe have traditionally required failure on older oral preventives before approving newer agents, a barrier that the TEMPLE safety endpoint directly challenges. Demonstrating lower discontinuation rates may persuade insurers to prioritize tolerability alongside cost, potentially unlocking broader reimbursement for Qulipta. Moreover, with Pfizer’s Nurtec and anti‑CGRP mAbs competing for market share, AbbVie’s oral gepant could capture patients seeking daily pills over injections, reshaping prescribing patterns and reinforcing the shift toward mechanism‑based migraine prevention.